polyethylenimine max (Kyfora Bio)
Kyfora Bio is a verified supplier 
Kyfora Bio manufactures this product 
99
Structured Review
Kyfora Bio
polyethylenimine max
Polyethylenimine Max, supplied by Kyfora Bio, used in various techniques. Bioz Stars score: 99/100, based on 5790 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pei+max+transfection+reagent/PEI+MAX+Transfection+Reagent/10__1096_slash_fj__202603205rr-60-27-31
Average 99 stars, based on 5790 article reviews
Polyethylenimine Max, supplied by Kyfora Bio, used in various techniques. Bioz Stars score: 99/100, based on 5790 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pei+max+transfection+reagent/PEI+MAX+Transfection+Reagent/10__1096_slash_fj__202603205rr-60-27-31
Average 99 stars, based on 5790 article reviews
polyethylenimine max - by Bioz Stars,
2026-10
99/100 stars
Images
Related Articles
Transfection:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used In Vivo:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used Control:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used Plasmid Preparation:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used Chloramphenicol Acetyltransferase Assay:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used Oligomer Restriction:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used shRNA:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used Incubator:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used Cotransfection:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used Flow Cytometry:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used Cell Culture:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used Cytometry:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used Expressing:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used Recombinant:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used Purification:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used Centrifugation:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used Chromatography:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used Vaccines:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used Affinity Chromatography:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used Isolation:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used Suspension:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used Expression Vector:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used Bicinchoninic Acid Protein Assay:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used Fluorescence:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used SDS Page:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used Knockdown:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used BIA-KA:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used Western Blot:Article Title: Engineering microRNAs as multimodal cancer therapeutics Article Snippet: rty given the persistent delivery challenges of miRNA therapeutics. However, vehicle-free cellular uptake should be distinguished from vehicle-free systemic delivery. The animal experiments still used |
